2025 ASCO GI | 强音继续，肝胆胰领域中国研究速览

前言

2025年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）将于1月23日至25日在美国加利福尼亚州旧金山举行，旨在为世界肿瘤学者传递国际消化肿瘤领域的最新研究进展。目前大会官网已披露了摘要标题，大会第二日聚焦肝胆胰领域研究进展，30项中国研究入选，医脉通特此整理相关摘要标题，诚邀您一同率先踏入这场科研之旅。

Rapid Oral Abstract Session

01

摘要号：LBA522

Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE).

经动脉化疗栓塞（TACE）联合卡瑞利珠单抗和阿帕替尼对比单纯TACE治疗符合栓塞条件的不可切除肝细胞癌：一项多中心、开放标签、随机、II期研究（CAP-ACE）

讲者：滕皋军 东南大学附属中大医院

Poster session

01

摘要号：531

MRI imaging and machine learning based radiomics for detection of mixed HCC and CCA tumors: Still a need for liver biopsy?

讲者：Yuquan Qian 中国医学科学院肿瘤医院

02

摘要号：533

Development and validation of the SPEAR scoring model and predicting overall survival in unresectable hepatocellular carcinoma patients treated with TACE, molecular targeted therapies, and immune checkpoint inhibitors.

讲者：Wenli Li 南方医科大学南方医院

03

摘要号：541

Regorafenib combined with immunotherapy and prognosis of unresectable hepatocellular carcinoma.

讲者：Tianxiang Li 青岛大学附属医院

04

摘要号：542

Concurrent transarterial chemoembolization plus atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: Interim analysis from a multicenter real-world study (CHANCE 023).

讲者：Rong Yan 东南大学附属中大医院

05

摘要号：553

Comparison of efficacy and safety of PD-1 and PD-L1 antibodies in combination with hepatic arterial infusion chemotherapy and target therapy for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study.

讲者：Xinhao Xiong 中山大学肿瘤防治中心

06

摘要号：562

A global comparative study on MDT practices in the management of hepatocellular carcinoma in high-income countries (HICs) and low- and middle-income countries (LMICs).

讲者：Huang Zhiyong 华中科技大学同济医学院附属同济医院

07

摘要号：563

Leading the way: How leading Chinese institutions drive MDT excellence in hepatocellular carcinoma.

讲者：Jiaping Li 中山大学附属第一医院

08

摘要号：568

Prompt initiation of durvalumab and tremelimumab treatment for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B.

讲者：Yu-Yun Shao 台湾大学医学院附设医院

09

摘要号：570

Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial).

讲者：匡铭 中山大学附属第一医院

10

摘要号：571

Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection.

讲者：Yiwen Chen 浙江大学医学院附属第一医院

11

摘要号：576

First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses.

讲者：赵明 中山大学肿瘤防治中心

12

摘要号：579

First-line iparomlimab and tuvonralimab (QL1706) or iparomlimab (QL1604) + bevacizumab (BEV) for unresectable hepatocellular carcinoma (HCC): Updated results from the phase Ib/II DUBHE-H-106 study.

讲者：毕锋四川大学华西医院

13

摘要号：580

Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma.

讲者：Feng Shi 广东省人民医院

14

摘要号：581

Selective internal radiation therapy with yttrium-90 resin microspheres followed by lenvatinib plus PD-1 inhibitor for large or huge advanced-stage hepatocellular carcinoma: A retrospective cohort study from China.

讲者：Jingjun Huang 广州医科大学附属第二医院

15

摘要号：585

Current status of physicians’ perception of HCC conversion/downstaging therapy: A nationwide survey in China.

讲者：Xinyu Bi 中国医学科学院肿瘤医院

16

摘要号：588

Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.

讲者：Zheng Wu 西安交通大学第一附属医院

17

摘要号：593

Surufatinib combined with locoregional therapies and immune checkpoint inhibitor (ICI) for treating unresectable or metastatic intrahepatic cholangiocarcinoma.

讲者：Wan Guang Zhang 华中科技大学同济医学院附属同济医院

18

摘要号：595

Efficacy and safety of durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib in advanced biliary tract cancer.

讲者：Haobin Yu 中国科学技术大学附属第一医院

19

摘要号：600

Long-term survival outcomes of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma.

讲者：Ching-Tso Chen 台湾大学医学院附设医院新竹台大分院

20

摘要号：601

Updated results of ALTER-H006: A phase II study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.

讲者：Xianhai Mao 中南大学湘雅医学院附属肿瘤医院

21

摘要号：622

Association of GPR120 and NGF with perineural invasion in cholangiocarcinoma: Clinical and experimental insights.

讲者：Jun He 苏州大学附属第一医院

22

摘要号：632

Exploring Nectin-4 expression in hepatocellular carcinoma.

讲者：Chien Huai Chuang 台湾大学癌症中心

23

摘要号：657

Efficacy and safety of surufatinib in unresectable or metastatic grade 3 pancreatic neuroendocrine tumors (NET G3): Real-world analysis.

讲者：Jian Wang 山东大学齐鲁医院

24

摘要号：714

The value and indications for surgery in pancreatic cancer with synchronous liver metastases.

讲者：Ruili Wei 中日友好医院

25

摘要号：729

Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine/nab-paclitaxel as first-line (1L) treatment in patients with Claudin18.2-positive locally advanced unresectable or metastatic (LA/m) pancreatic cancer.

讲者：刘福囝 中国医科大学附属第一医院

26

摘要号：734

The effect of renin-angiotensin system inhibitors on patients with pancreatic cancer receiving systemic treatment: A retrospective cohort study from TriNetX US collaborative networks.

讲者：Cheng-Wei Chou 台中荣民总医院

27

摘要号：739

Surufatinib combined with TAS-102 as a late-line therapy in patients with metastatic pancreatic cancer (mPDAC): Updated results of a single-arm, phase II trial.

讲者：张东生 中山大学肿瘤防治中心

28

摘要号：740

Chidamide plus envafolimab combined with S-1 as second-line treatment in advanced and metastatic pancreatic cancer (P-henomS/SCOG-P002): A single-arm, exploratory, multicenter, phase 2 trial—Interim report.

讲者：Wei Li 苏州大学附属第一医院

29

摘要号：774

Personalized ctDNA monitoring to assess the recurrence of early stage pancreatic cancer after surgery.

讲者：杜娟 南京鼓楼医院

Trials in Progress Poster Session

01

摘要号：TPS650

AMBER part 2F: Cobolimab in combination with dostarlimab in treatment-naïve patients with locally advanced/metastatic and/or unresectable hepatocellular carcinoma (HCC).

讲者：Stephen Lam Chan 香港中文大学

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~

撰写：Babel

排版：Aurora

执行：Babel

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。